Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 43 of 100, showing 5 Applications out of 500 total, starting on record 211, ending on 215

# Protocol No Study Title Investigator(s) & Site(s)

211.

ECCT/21/05/07   CoVPN 3008
    Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern   
Principal Investigator(s)
1. Grace Mboya Mugure
Site(s) in Kenya
1. KEMRI CGHR Kisumu Clinical Research Site (Kisumu county)
 
View

212.

ECCT/21/05/05   The “EMPATHY” Trial
    A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19.       
Principal Investigator(s)
1. DR LUCAS OTIENO TINA
2. Dr. Bernhards Ragama Ogutu
3. Dr Deborah Chepngeno Langat
4. Dr Videlis Nduba Nduba
5. Dr Janet Oyieko
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. Kenyatta University Teaching Referral and Research Hospital (KUTRRH) (Nairobi City county)
3. Kenya Medical Research Institute/US Army Medical Research Directorate-Kenya-Kericho (Kericho county)
4. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
5. KEMRI-USAMRD-A, Kisumu Field Station (Kisumu county)
 
View

213.

ECCT/21/05/04   Multi-nutrients in ADHD
    Broad spectrum micronutrient supplementation in the management of ADHD symptoms:a clinical trial   
Principal Investigator(s)
1. Maureen Muthoni Njoroge
Site(s) in Kenya
Kenyatta National Hospital
 
View

214.

ECCT/21/05/01   ZAZA study
    Zinc isotope study: Assessing Zinc absorption from edible insects in young children   
Principal Investigator(s)
1. Dr. Alida Melse-Boonstra Melse-Boonstra
Site(s) in Kenya
Ober-Kamoth sub-county hospital - Level 4 Health Facility
 
View

215.

ECCT/21/05/06   VAC52150EBL2010 ;Phase 2
    An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen   
Principal Investigator(s)
1. Prof. Omu Anzala Omu Anzala
Site(s) in Kenya
KAVI-institute of Clinical Research
 
View